Cargando...

A Novel Adenylyl Cyclase Type 5 Inhibitor That Reduces Myocardial Infarct Size Even When Administered After Coronary Artery Reperfusion

We developed a novel adenylyl cyclase type 5 (AC5) inhibitor, C90, that reduces myocardial infarct size even when administered after coronary reperfusion. This is key, since it is not practical to administer a drug to a patient with myocardial infarction before revascularization, and is one reason w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Mol Cell Cardiol
Main Authors: Zhang, Jie, Levy, Daniel, Oydanich, Marko, Bravo, Claudio, Yoon, Seonghun, Vatner, Dorothy E., Vatner, Stephen F.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6103820/
https://ncbi.nlm.nih.gov/pubmed/29800555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yjmcc.2018.05.014
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!